Alvine Pharmaceuticals (Asstes) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Alvine Pharmaceuticals (Asstes) General Information

Description

The assets include ALV003, a mixture of two gluten-specific recombinant proteases engineered to digest gluten and to treat patients with celiac disease. Latiglutenase (formerly known as ALV003 and renamed IMGX-003) is an orally administered mixture of two recombinant gluten-specific proteases including glutamine-specific cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) to treat celiac disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Shoreway Road
  • Suite B
  • San Carlos, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Shoreway Road
  • Suite B
  • San Carlos, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alvine Pharmaceuticals (Asstes) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alvine Pharmaceuticals (Asstes)‘s full profile, request access.

Request a free trial

Alvine Pharmaceuticals (Asstes) FAQs

  • Where is Alvine Pharmaceuticals (Asstes) headquartered?

    Alvine Pharmaceuticals (Asstes) is headquartered in San Carlos, CA.

  • What industry is Alvine Pharmaceuticals (Asstes) in?

    Alvine Pharmaceuticals (Asstes)’s primary industry is Buildings and Property.

  • Is Alvine Pharmaceuticals (Asstes) a private or public company?

    Alvine Pharmaceuticals (Asstes) is a Private company.

  • What is Alvine Pharmaceuticals (Asstes)’s current revenue?

    The current revenue for Alvine Pharmaceuticals (Asstes) is .

  • When was Alvine Pharmaceuticals (Asstes) acquired?

    Alvine Pharmaceuticals (Asstes) was acquired on 15-Mar-2016.

  • Who acquired Alvine Pharmaceuticals (Asstes)?

    Alvine Pharmaceuticals (Asstes) was acquired by ImmunogenX.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process